Indoco Remedies Limited stock analysis
Want to see IN:INDOCO full AI Analyst Report?
Indoco Remedies Limited (INDOCO) Stock Price & Analysis
INDOCO Stock Chart & Stats
- Day’s Range
- INR 226.75 - INR 254.75
- 52-Week Range
- INR 163.70 - INR 287.35
- Previous Close
- INR 224.60
- Volume
- 80.97K
- Average Volume (3M)
- 26.84K
- Market Cap
- INR 22.26B
- Enterprise Value
- INR 34.26B
- Total Cash (Recent Filing)
- INR 589.90M
- Total Debt (Recent Filing)
- INR 10.59B
- Price to Earnings (P/E)
- 71.2
- Beta
- 0.92
- Next Earnings
- Jan 26, 2027 (Est.)
- EPS Estimate
- 2.6
- Last Dividend Ex-Date
- Sep 10, 2026
- Dividend Yield
- 0.08%
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Positive revenue growth indicates that the company continues to expand demand for its pharmaceutical products despite recent profitability pressure. Sustained top-line progress across domestic and international markets can support operating recovery if management converts sales growth into stronger margins.
Gross Margin
A gross margin of roughly 41% provides an important economic foundation for the business and shows that product-level economics remain reasonable. The improvement versus FY2024 creates potential for better earnings conversion if operating costs and other pressures are brought under control.
Business Model Breadth
Exposure to branded and generic formulations, APIs, contract manufacturing, and multiple therapeutic segments gives Indoco several routes to generate pharmaceutical revenue. Its domestic and international presence can broaden commercial reach and reduce reliance on a single product category.
Bears Say
Sustained Losses And Margin Compression
Two consecutive annual losses and an EBIT margin near 0.8% show that recent revenue growth is not translating into adequate operating profitability. Continued margin weakness could restrict reinvestment, weaken returns, and delay a durable recovery in shareholder earnings.
Higher Leverage
The sharp increase in debt relative to equity reduces financial flexibility while the company is reporting losses and negative returns. Higher leverage can increase the importance of earnings recovery, constrain capital allocation, and make the balance sheet more sensitive to prolonged operating weakness.
Negative Free Cash Flow
Deeply negative free cash flow indicates that operating cash generation has not covered investment and other cash requirements in the latest two years. This can limit internally funded growth, increase dependence on financing, and heighten execution risk if outflows remain elevated.
Indoco Remedies Limited News
INDOCO FAQ
What was Indoco Remedies Limited’s price range in the past 12 months?
What is Indoco Remedies Limited’s market cap?
When is Indoco Remedies Limited’s upcoming earnings report date?
How were Indoco Remedies Limited’s earnings last quarter?
Is Indoco Remedies Limited overvalued?
Does Indoco Remedies Limited pay dividends?
What is Indoco Remedies Limited’s EPS estimate?
How many shares outstanding does Indoco Remedies Limited have?
What happened to Indoco Remedies Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Indoco Remedies Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Indoco Remedies Limited
Indoco Remedies Limited, an Indian pharmaceutical company founded in Mumbai in 1945 (originally known as Indo Continental Trading Company), operates globally, manufacturing and distributing a broad spectrum of finished drug formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses diverse therapeutic areas: Respiratory conditions: with offerings like Karvol Plus, Febrex Plus, and Tuspel. Oral and dental care (stomatologicals): including Sensodent-K, Sensoform Toothpaste, the Rexidin series, and Snowdent. Gastrointestinal ailments: featuring products such as Carmicide, Cyclopam, and Nosic. Pain relief/analgesics: exemplified by Lignox and T-lac. Ophthalmic and otic solutions: comprising items like Renolen, Dexoren – S, and the Mofloren range. Vitamins, minerals, and nutritional supplements: such as Methycal, MCBM DHA, and Apispur. Urological treatments: including Carmicide and Cital. Dermatological preparations: like Cloben G and Scabex. Anti-infective agents: represented by ATM. Blood-related therapies: such as Hemsyl. Gynecological health products: including MCBM 69 and D Chiro. Anti-haemorrhoidal treatments: with Spear. Beyond its pharmaceutical manufacturing, Indoco Remedies provides comprehensive analytical services. These include impurity profiling, particle size analysis, heavy metal analysis, polymorphism studies, compatibility and stability assessments (like extractables/leachables and lyophilization), and advanced chromatographic method development and validation. Furthermore, the company offers a suite of engineering and project management services. This covers architectural and structural design, mechanical and electrical engineering, lighting solutions, control system integration, piping design, data transfer systems, and holistic project and construction management for process facilities. Indoco Remedies serves a wide range of medical professionals, from general practitioners and pediatricians to specialized consultants like dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Aditi Kare Panandikar
- Employees
- 6,000
- Website
- www.indoco.com
- Address
- Indoco House, Mumbai, MA, 400098, IN
Indoco Remedies Limited (INDOCO) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 4 | 2 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 12 | 0 | 0 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:APLLTDAlembic Pharmaceuticals Limited | ||
| IN:HIKALHikal Limited | ||
| IN:MOREPENLABMorepen Laboratories Limited | ||
| IN:SOLARASolara Active Pharma Sciences Ltd. | ||
| IN:UNICHEMLABUnichem Laboratories Limited |










